T
he vast majority of osteoporosis treatment are currently controlling the process of bone resorption. Salaries promoting the manufacture of bones are found, however, exceptions.They are expensive, administered by injection or accompanied by an increased risk of breast cancer as in the case of hormonal treatments intended to offset the decline in estrogen.
Approximately 400 000 Quebecoises currently suffer menopausal osteoporosis. For these women, a banal fall can often result in a serious fracture.
The mechanism of regeneration of bone tiring with age and bones of people suffering from osteoporosis more easily, these fractures are often more difficult to repair.
The work of Dr. Buckbinder, central research and development of the pharmaceutical company Pfizer in Connecticut, raised new hope. The researcher was interested in PYK2 enzyme, known to play a role in the formation mechanisms and resorption of bone.
He discovered that the enzyme inhibits the formation of bone. In the blocking, it would be possible to halt the inhibition and therefore, to restore the formation of bone.
Dr. Jacques Brown, head of rheumatology at University Hospital of Quebec is excited by the results obtained by his colleague. According to him, "its results are fascinating! "And is" an interesting step forward "toward finding new osteoporosis treatment promoting bone formation.
Moreover, by the nature of the inhibitor used, the cost of that osteoporosis treatment should be more affordable and oral administration would confer a real advantage.
It remains, however, to pursue studies including clinical trials to ensure the absence of undesirable side effects.
